var data={"title":"Paroxysmal hemicrania: Treatment and prognosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Paroxysmal hemicrania: Treatment and prognosis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/contributors\" class=\"contributor contributor_credentials\">Manjit S Matharu, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/contributors\" class=\"contributor contributor_credentials\">Anna S Cohen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/contributors\" class=\"contributor contributor_credentials\">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/contributors\" class=\"contributor contributor_credentials\">John F Dashe, MD, PhD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 02, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/1,2\" class=\"abstract_t\">1,2</a>]. The TACs include cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks, and hemicrania continua [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Despite their common elements, the TACs differ in attack duration and frequency, as well as the response to therapy (<a href=\"image.htm?imageKey=NEURO%2F65541\" class=\"graphic graphic_table graphicRef65541 \">table 1</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemicrania continua is characterized by continuous pain with exacerbations</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cluster headache has a relatively long attack duration and relatively low attack frequency</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Paroxysmal hemicrania has intermediate attack duration and frequency</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Short-lasting unilateral neuralgiform headache attacks have the shortest attack duration and the highest attack frequency</p><p/><p>The importance of recognizing these syndromes resides in their selective response to treatment. Both hemicrania continua and paroxysmal hemicrania respond in a dramatic and absolute fashion to <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>, unlike cluster headache and the syndrome of short-lasting unilateral neuralgiform headache attacks.</p><p>This topic will review the treatment and prognosis of paroxysmal hemicrania. Other clinical aspects of paroxysmal hemicrania are reviewed separately. (See <a href=\"topic.htm?path=paroxysmal-hemicrania-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Paroxysmal hemicrania: Clinical features and diagnosis&quot;</a>.)</p><p>Other trigeminal autonomic cephalalgias are discussed elsewhere. (See <a href=\"topic.htm?path=hemicrania-continua\" class=\"medical medical_review\">&quot;Hemicrania continua&quot;</a> and <a href=\"topic.htm?path=cluster-headache-epidemiology-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Cluster headache: Epidemiology, clinical features, and diagnosis&quot;</a> and <a href=\"topic.htm?path=short-lasting-unilateral-neuralgiform-headache-attacks-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=pathophysiology-of-the-trigeminal-autonomic-cephalalgias\" class=\"medical medical_review\">&quot;Pathophysiology of the trigeminal autonomic cephalalgias&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PHARMACOLOGIC TREATMENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of paroxysmal hemicrania is entirely prophylactic, as attacks are too short and intense for any acute oral treatment to be effective. <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">Indomethacin</a> is the treatment of choice for adults and children with paroxysmal hemicrania. Because it is rare, and because indomethacin is highly effective, there are no large prospective clinical trials evaluating therapy for paroxysmal hemicrania.</p><p>For patients who cannot tolerate <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>, one faces a difficult challenge. No other drug is consistently effective in paroxysmal hemicrania. Alternative drug therapies that may be useful are reviewed below.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Indomethacin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>By definition, paroxysmal hemicrania responds completely to <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>. (See <a href=\"topic.htm?path=paroxysmal-hemicrania-clinical-features-and-diagnosis#H15\" class=\"medical medical_review\">&quot;Paroxysmal hemicrania: Clinical features and diagnosis&quot;, section on 'Diagnostic criteria'</a>.)</p><p>Evidence supporting the effectiveness of <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> comes mainly from observational case series [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/4-7\" class=\"abstract_t\">4-7</a>]. In the two largest series, the following observations were reported:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a prospective study of 31 patients with paroxysmal hemicrania, 30 patients could tolerate <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>, and all had a positive response [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/7\" class=\"abstract_t\">7</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective study with data for <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> response in 40 patients diagnosed with chronic paroxysmal hemicrania, a consistent response to indomethacin was noted in 30 (75 percent). Of the 30 consistent responders, 24 had complete response, while six patients had a partial response. An inconsistent response was observed in 10 (25 percent) [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/4\" class=\"abstract_t\">4</a>]. While patients with an inconsistent response did not meet strict diagnostic criteria for paroxysmal hemicrania, the investigators noted that all had a headache phenotype that best fit with paroxysmal hemicrania rather than cluster headache.</p><p/><p>The existence of indomethacin-insensitive paroxysmal hemicrania is controversial. However, there are reports of patients who have clinical symptoms consistent with paroxysmal hemicrania, yet do not respond to <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/4,8\" class=\"abstract_t\">4,8</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">Dosage and side effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The starting dose of <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> for adults and older adolescents (&ge;15 years of age) is 75 mg daily in three divided doses (ie, 25 mg three times a day). The indomethacin dose should be increased to 150 mg daily in three divided doses for 3 to 10 days if there is an incomplete response to the starting dose after 3 days. The dose should be further increased to 225 mg daily in three divided doses for 10 days for partial responders if the index of suspicion is high.</p><p>For children (&le;14 years of age), the <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> dose is 1 to 2 <span class=\"nowrap\">mg/kg</span> daily given in two divided doses [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/9\" class=\"abstract_t\">9</a>].</p><p>The use of <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> to confirm the diagnosis of paroxysmal hemicrania is reviewed separately. (See <a href=\"topic.htm?path=paroxysmal-hemicrania-clinical-features-and-diagnosis#H17\" class=\"medical medical_review\">&quot;Paroxysmal hemicrania: Clinical features and diagnosis&quot;, section on 'Indomethacin trial'</a>.)</p><p>Complete resolution of the headache is typically prompt, usually occurring within one to two days of initiating the effective <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> dose. In patients who do not respond to indomethacin, the diagnosis of paroxysmal hemicrania should be reconsidered.</p><p>The typical maintenance dose of <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> is 25 to 100 mg daily. However, the effective maintenance dose can vary between 12.5 and 300 mg daily, depending on individual response and the fluctuation in attack severity [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/10\" class=\"abstract_t\">10</a>]. Hence, dosage adjustments may be necessary to address the clinical fluctuations seen in paroxysmal hemicrania.</p><p>Suspicion for a secondary cause of paroxysmal hemicrania should be raised in patients who need escalating doses or become refractory to <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> treatment. Similarly, underlying pathology may be present in patients who require continuous high doses of indomethacin [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/11\" class=\"abstract_t\">11</a>]. In such cases, we recommend careful diagnostic evaluation (or re-evaluation) for secondary causes, including brain imaging. (See <a href=\"topic.htm?path=paroxysmal-hemicrania-clinical-features-and-diagnosis#H20\" class=\"medical medical_review\">&quot;Paroxysmal hemicrania: Clinical features and diagnosis&quot;, section on 'Laboratory investigations'</a> and <a href=\"topic.htm?path=paroxysmal-hemicrania-clinical-features-and-diagnosis#H22\" class=\"medical medical_review\">&quot;Paroxysmal hemicrania: Clinical features and diagnosis&quot;, section on 'Secondary paroxysmal hemicrania'</a>.)</p><p>Most patients can expect sustained efficacy of <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> treatment without developing tachyphylaxis, though about one-quarter develop gastrointestinal side effects [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/12\" class=\"abstract_t\">12</a>]. The most common serious side effect of indomethacin is the development of peptic ulcers. Measures to prevent gastrointestinal side effects include testing and treating for Helicobacter pylori, and the use of gastroprotection with <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> or proton pump inhibitors. These issues are discussed separately. (See <a href=\"topic.htm?path=nsaids-including-aspirin-primary-prevention-of-gastroduodenal-toxicity#H10\" class=\"medical medical_review\">&quot;NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity&quot;, section on 'Prevention strategies'</a>.)</p><p><a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">Indomethacin</a> suppositories are occasionally helpful if gastric intolerance is a major problem, or when high doses, such as 300 mg daily, are required. </p><p>Nonselective NSAIDs such as <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> also have potentially important renal and cardiovascular effects. Renal adverse effects include acute renal failure due to renal vasoconstriction, worsening of underlying hypertension, and electrolyte and fluid abnormalities. Additionally, the risk of renal cell cancer may be increased. Cardiovascular effects include interference by some agents with the antiplatelet activity of <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, an effect on coronary risk, and worsening of heart failure. (See <a href=\"topic.htm?path=nonselective-nsaids-overview-of-adverse-effects\" class=\"medical medical_review\">&quot;Nonselective NSAIDs: Overview of adverse effects&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Indomethacin discontinuation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Upon discontinuation of <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>, symptoms of paroxysmal hemicrania usually reappear within 12 hours to two weeks. During active headache cycles, however, skipping or even delaying doses may result in the prompt reoccurrence of the headache [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/5\" class=\"abstract_t\">5</a>].</p><p><a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">Indomethacin</a> withdrawal strategies differ for patients with episodic and chronic forms of paroxysmal hemicrania.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with episodic paroxysmal hemicrania, <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> should be given for slightly longer than the typical headache bout and then gradually tapered.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with chronic paroxysmal hemicrania, long-term treatment is usually necessary. However, long-lasting remissions have been reported in rare patients following cessation of <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>. Thus, we suggest an indomethacin drug withdrawal trial at least once every six months for patients with chronic paroxysmal hemicrania. This should be done by gradually tapering the dose of indomethacin.</p><p/><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Alternative drug therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted above, patients who cannot tolerate <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> face a difficult challenge, since no other drug is consistently effective in paroxysmal hemicrania. Alternative drug therapies that may have some benefit for paroxysmal hemicrania include nonsteroidal antiinflammatory drugs (NSAIDs) other than indomethacin, calcium channel blockers, and several miscellaneous agents.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Other nonsteroidal antiinflammatory drugs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Numerous other NSAIDs have been tried in paroxysmal hemicrania but none show the consistent and exquisite response provided by <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>. The NSAIDs that have been reported to be partially or completely effective, mainly in isolated cases, include <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/13-15\" class=\"abstract_t\">13-15</a>], <a href=\"topic.htm?path=ibuprofen-drug-information\" class=\"drug drug_general\">ibuprofen</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/15\" class=\"abstract_t\">15</a>], <a href=\"topic.htm?path=naproxen-drug-information\" class=\"drug drug_general\">naproxen</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/15-18\" class=\"abstract_t\">15-18</a>], <a href=\"topic.htm?path=diclofenac-drug-information\" class=\"drug drug_general\">diclofenac</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/15,19\" class=\"abstract_t\">15,19</a>], <a href=\"topic.htm?path=ketoprofen-drug-information\" class=\"drug drug_general\">ketoprofen</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/13\" class=\"abstract_t\">13</a>], and <a href=\"topic.htm?path=piroxicam-drug-information\" class=\"drug drug_general\">piroxicam</a> beta-cyclodextrin [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/20\" class=\"abstract_t\">20</a>].</p><p>Limited success in the treatment of paroxysmal hemicrania has been reported with the cyclooxygenase-2 (COX-2) inhibitors rofecoxib [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/21-23\" class=\"abstract_t\">21-23</a>] and <a href=\"topic.htm?path=celecoxib-drug-information\" class=\"drug drug_general\">celecoxib</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/21,24\" class=\"abstract_t\">21,24</a>]. However, prolonged use of these agents is associated with an increased risk of myocardial infarction and stroke and rofecoxib was withdrawn from the worldwide market in 2004. (See <a href=\"topic.htm?path=cox-2-selective-inhibitors-adverse-cardiovascular-effects\" class=\"medical medical_review\">&quot;COX-2 selective inhibitors: Adverse cardiovascular effects&quot;</a>.)</p><p>Given the risk of ischemic cardiovascular disease, the available COX-2 inhibitors should be prescribed only with great caution in paroxysmal hemicrania.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Calcium channel antagonists</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are several case reports of patients with paroxysmal hemicrania who had a partial or complete response to <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/15,25-28\" class=\"abstract_t\">15,25-28</a>], and verapamil is generally considered the best alternative drug treatment to <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> for paroxysmal hemicrania [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/29\" class=\"abstract_t\">29</a>]. Other calcium channel antagonists that have been reported to be effective in paroxysmal hemicrania include <a href=\"topic.htm?path=flunarizine-united-states-not-available-drug-information\" class=\"drug drug_general\">flunarizine</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/15,30\" class=\"abstract_t\">15,30</a>] and <a href=\"topic.htm?path=nicardipine-drug-information\" class=\"drug drug_general\">nicardipine</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/30\" class=\"abstract_t\">30</a>].</p><p>Given these data, we suggest <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a> for patients with paroxysmal hemicrania who are unable to tolerate <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>. Similarly, we suggest verapamil for patients with a clinical phenotype of paroxysmal hemicrania who have an incomplete or poor response to an adequate trial of indomethacin. Verapamil is usually started at 160 to 240 mg daily in two divided doses. A lower starting dose of 80 mg daily in two divided doses is suggested for patients who are elderly or of small stature. The dose can be increased as needed and as tolerated up to 480 mg daily in three to four divided doses. Most responders require a dose of 240 to 320 mg daily.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Miscellaneous drugs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other drugs reported to be partially or completely effective in paroxysmal hemicrania, mainly in isolated cases, include <a href=\"topic.htm?path=acetazolamide-drug-information\" class=\"drug drug_general\">acetazolamide</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/31\" class=\"abstract_t\">31</a>], <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/13,17\" class=\"abstract_t\">13,17</a>], ergotamines [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/13\" class=\"abstract_t\">13</a>], <a href=\"topic.htm?path=sumatriptan-drug-information\" class=\"drug drug_general\">sumatriptan</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/15,32,33\" class=\"abstract_t\">15,32,33</a>], and <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/13\" class=\"abstract_t\">13</a>].</p><p class=\"headingAnchor\" id=\"H11812155\"><span class=\"h2\">Children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As in adults, <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> is the treatment of choice for children and adolescents with paroxysmal hemicrania [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/9\" class=\"abstract_t\">9</a>]. (See <a href=\"#H3\" class=\"local\">'Indomethacin'</a> above.)</p><p>For children who cannot tolerate <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>, a number of second-line treatments have been tried; the list includes cyclooxygenase-2 inhibitors, calcium channel antagonists (eg, <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a>, <a href=\"topic.htm?path=flunarizine-united-states-not-available-drug-information\" class=\"drug drug_general\">flunarizine</a>), <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">topiramate</a>, and greater occipital nerve blocks [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/9\" class=\"abstract_t\">9</a>]. However, none are as effective as indomethacin.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">ALTERNATIVE THERAPIES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Alternative approaches for the treatment of paroxysmal hemicrania include local blockades, neurostimulation, and surgical procedures.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Local blockades</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Local anesthetic blockades of pericranial nerves, including the greater occipital nerve, supraorbital nerve, and lesser occipital nerve, have been generally ineffective for paroxysmal hemicrania, as have stellate ganglion blocks, sphenopalatine ganglion blocks, and cervical sympathetic blocks [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/13,34\" class=\"abstract_t\">13,34</a>].</p><p>However, there are two reports of complete response with local blockades. One was a patient with episodic paroxysmal hemicrania who consistently showed a complete response to greater occipital nerve blockade with a combination of <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> and <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a>, but not <a href=\"topic.htm?path=bupivacaine-drug-information\" class=\"drug drug_general\">bupivacaine</a> [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/35\" class=\"abstract_t\">35</a>]. Another case report described complete response to repetitive sympathetic chain block with a combination of bupivacaine and methylprednisolone introduced onto the C7 transverse process, but not with saline placebo [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/36\" class=\"abstract_t\">36</a>]. This patient subsequently had a stellate ganglionectomy (sympathectomy) that rendered him pain-free, though follow-up was limited to 15 months.</p><p class=\"headingAnchor\" id=\"H1058603974\"><span class=\"h2\">Neurostimulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Retrospective case reports and observational studies have reported improvement of paroxysmal hemicrania in small numbers of patients treated with various neurostimulation techniques, including occipital nerve stimulation [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/37\" class=\"abstract_t\">37</a>], percutaneous vagus nerve stimulation [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/38\" class=\"abstract_t\">38</a>], and deep brain stimulation [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/39\" class=\"abstract_t\">39</a>]. However, the actual benefit of each of these treatments should be considered unknown until more definitive evidence is available.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Invasive surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>With the exception of one report of benefit with stellate ganglionectomy discussed above [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/36\" class=\"abstract_t\">36</a>], invasive surgical procedures, including trigeminal sensory root section, infraorbital nerve section, superficial petrosal nerve section, and sphenopalatine ganglionectomy, have been ineffective [<a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/13,36\" class=\"abstract_t\">13,36</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">NATURAL HISTORY AND PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Paroxysmal hemicrania is a rare syndrome, and there is a paucity of literature on its natural history and long-term prognosis. The available evidence suggests that it is a lifelong condition. Patients generally obtain sustained relief with <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> treatment. (See <a href=\"#H3\" class=\"local\">'Indomethacin'</a> above.)</p><p><a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">Indomethacin</a> does not seem to alter the condition in the long-term, though a significant portion of patients can decrease the dose of indomethacin required to maintain a pain-free state.</p><p class=\"headingAnchor\" id=\"H678085210\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-migraine-and-other-primary-headache-disorders\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Migraine and other primary headache disorders&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The treatment of paroxysmal hemicrania is prophylactic, as attacks are too short and intense for any acute oral treatment to be effective. (See <a href=\"#H2\" class=\"local\">'Pharmacologic treatments'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For adults and children with a paroxysmal hemicrania, we recommend treatment with <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>&nbsp;(<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). Starting doses and dosage adjustments are discussed above. Gastrointestinal side effects are common with this therapy. (See <a href=\"#H3\" class=\"local\">'Indomethacin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">Indomethacin</a> withdrawal strategies differ for patients with episodic and chronic forms of paroxysmal hemicrania. (See <a href=\"#H5\" class=\"local\">'Indomethacin discontinuation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with paroxysmal hemicrania who are unable to tolerate <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>, and for patients with a clinical phenotype of paroxysmal hemicrania who have an incomplete or poor response to an adequate trial of indomethacin, we suggest treatment with <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a>&nbsp;(<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Reasonable alternatives include <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> and other NSAIDS, such as <a href=\"topic.htm?path=naproxen-drug-information\" class=\"drug drug_general\">naproxen</a> and <a href=\"topic.htm?path=diclofenac-drug-information\" class=\"drug drug_general\">diclofenac</a>. (See <a href=\"#H9\" class=\"local\">'Calcium channel antagonists'</a> above and <a href=\"#H8\" class=\"local\">'Other nonsteroidal antiinflammatory drugs'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>With the exception of isolated case reports, local anesthetic blockades of pericranial nerves and invasive surgical procedures have been generally ineffective for the treatment of paroxysmal hemicrania. (See <a href=\"#H11\" class=\"local\">'Alternative therapies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The available evidence suggests that paroxysmal hemicrania is a lifelong condition. Patients generally obtain sustained relief with <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a> treatment. (See <a href=\"#H14\" class=\"local\">'Natural history and prognosis'</a> above.)</p><p/><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/1\" class=\"nounderline abstract_t\">Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain 1997; 120 ( Pt 1):193.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/2\" class=\"nounderline abstract_t\">Goadsby PJ. Trigeminal autonomic cephalalgias. Pathophysiology and classification. Rev Neurol (Paris) 2005; 161:692.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/3\" class=\"nounderline abstract_t\">Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/4\" class=\"nounderline abstract_t\">Boes CJ, Dodick DW. Refining the clinical spectrum of chronic paroxysmal hemicrania: a review of 74 patients. Headache 2002; 42:699.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/5\" class=\"nounderline abstract_t\">Sjaastad O, Apfelbaum R, Caskey W, et al. Chronic paroxysmal hemicrania (CPH). The clinical manifestations. A review. Ups J Med Sci Suppl 1980; 31:27.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/6\" class=\"nounderline abstract_t\">Matharu MS, Cohen AS, Frackowiak RS, Goadsby PJ. Posterior hypothalamic activation in paroxysmal hemicrania. Ann Neurol 2006; 59:535.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/7\" class=\"nounderline abstract_t\">Cittadini E, Matharu MS, Goadsby PJ. Paroxysmal hemicrania: a prospective clinical study of 31 cases. Brain 2008; 131:1142.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/8\" class=\"nounderline abstract_t\">Fuad F, Jones NS. Paroxysmal hemicrania and cluster headache: two discrete entities or is there an overlap? Clin Otolaryngol Allied Sci 2002; 27:472.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/9\" class=\"nounderline abstract_t\">Lambru G, Matharu M. Management of trigeminal autonomic cephalalgias in children and adolescents. Curr Pain Headache Rep 2013; 17:323.</a></li><li class=\"breakAll\">Sjaastad, O. Chronic paroxysmal hemicrania. In: Handbook of Clinical Neurology, Vol.48, Vinken, PJ, Bruyn, GW, Klawans, HL, Rose, FC (Eds). Elsevier Science, Amsterdam 1986. p.257.</li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/11\" class=\"nounderline abstract_t\">Sjaastad O, Stovner LJ, Stolt-Nielsen A, et al. CPH and hemicrania continua: requirements of high indomethacin dosages--an ominous sign? Headache 1995; 35:363.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/12\" class=\"nounderline abstract_t\">Pareja JA, Caminero AB, Franco E, et al. Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua. Cephalalgia 2001; 21:906.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/13\" class=\"nounderline abstract_t\">Antonaci F, Sjaastad O. Chronic paroxysmal hemicrania (CPH): a review of the clinical manifestations. Headache 1989; 29:648.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/14\" class=\"nounderline abstract_t\">Kudrow DB, Kudrow L. Successful aspirin prophylaxis in a child with chronic paroxysmal hemicrania. Headache 1989; 29:280.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/15\" class=\"nounderline abstract_t\">Evers S, Husstedt IW. Alternatives in drug treatment of chronic paroxysmal hemicrania. Headache 1996; 36:429.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/16\" class=\"nounderline abstract_t\">Mateo I, Pascual J. Coexistence of chronic paroxysmal hemicrania and benign cough headache. Headache 1999; 39:437.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/17\" class=\"nounderline abstract_t\">Hannerz J, Ericson K, Bergstrand G. Chronic paroxysmal hemicrania: orbital phlebography and steroid treatment. A case report. Cephalalgia 1987; 7:189.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/18\" class=\"nounderline abstract_t\">Durko, A, Klimek, A. Naproxen in the treatment of chronic paroxysmal hemicrania. Cephalalgia 1987; 7:361.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/19\" class=\"nounderline abstract_t\">Pradalier A, Dry J. [Chronic paroxysmal hemicrania. Treatment with indomethacin and diclofenac]. Therapie 1984; 39:185.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/20\" class=\"nounderline abstract_t\">Sjaastad O, Antonaci F. A piroxicam derivative partly effective in chronic paroxysmal hemicrania and hemicrania continua. Headache 1995; 35:549.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/21\" class=\"nounderline abstract_t\">Siow HC. Seasonal episodic paroxysmal hemicrania responding to cyclooxygenase-2 inhibitors. Cephalalgia 2004; 24:414.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/22\" class=\"nounderline abstract_t\">Chakravarty A, Mukherjee A, Roy D. Trigeminal autonomic cephalgias and variants: clinical profile in Indian patients. Cephalalgia 2004; 24:859.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/23\" class=\"nounderline abstract_t\">Lisotto C, Maggioni F, Mainardi F, Zanchin G. Rofecoxib for the treatment of chronic paroxysmal hemicrania. Cephalalgia 2003; 23:318.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/24\" class=\"nounderline abstract_t\">Mathew NT, Kailasam J, Fischer A. Responsiveness to celecoxib in chronic paroxysmal hemicrania. Neurology 2000; 55:316.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/25\" class=\"nounderline abstract_t\">Zidverc-Trajkovic J, Pavlovic AM, Mijajlovic M, et al. Cluster headache and paroxysmal hemicrania: differential diagnosis. Cephalalgia 2005; 25:244.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/26\" class=\"nounderline abstract_t\">de Almeida DB, Cunali PA, Santos HL, et al. Chronic paroxysmal hemicrania in early childhood: case report. Cephalalgia 2004; 24:608.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/27\" class=\"nounderline abstract_t\">Schlake HP, B&ouml;ttger IG, Grotemeyer KH, et al. Single photon emission computed tomography (SPECT) with 99mTc-HMPAO (hexamethyl propylenamino oxime) in chronic paroxysmal hemicrania--a case report. Cephalalgia 1990; 10:311.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/28\" class=\"nounderline abstract_t\">Shabbir N, McAbee G. Adolescent chronic paroxysmal hemicrania responsive to verapamil monotherapy. Headache 1994; 34:209.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/29\" class=\"nounderline abstract_t\">May A, Leone M, Afra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 2006; 13:1066.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/30\" class=\"nounderline abstract_t\">Coria F, Claveria LE, Jimenez-Jimenez FJ, de Seijas EV. Episodic paroxysmal hemicrania responsive to calcium channel blockers. J Neurol Neurosurg Psychiatry 1992; 55:166.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/31\" class=\"nounderline abstract_t\">Warner JS, Wamil AW, McLean MJ. Acetazolamide for the treatment of chronic paroxysmal hemicrania. Headache 1994; 34:597.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/32\" class=\"nounderline abstract_t\">Pascual J, Quijano J. A case of chronic paroxysmal hemicrania responding to subcutaneous sumatriptan. J Neurol Neurosurg Psychiatry 1998; 65:407.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/33\" class=\"nounderline abstract_t\">Hannerz J, Jogestrand T. Intracranial hypertension and sumatriptan efficacy in a case of chronic paroxysmal hemicrania which became bilateral. (The mechanism of indomethacin in CPH). Headache 1993; 33:320.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/34\" class=\"nounderline abstract_t\">Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua: anaesthetic blockades of pericranial nerves. Funct Neurol 1997; 12:11.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/35\" class=\"nounderline abstract_t\">Rossi P, Di Lorenzo G, Faroni J, Sauli E. Seasonal, extratrigeminal, episodic paroxysmal hemicrania successfully treated with single suboccipital steroid injections. Eur J Neurol 2005; 12:903.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/36\" class=\"nounderline abstract_t\">Albertyn J, Barry R, Odendaal CL. Cluster headache and the sympathetic nerve. Headache 2004; 44:183.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/37\" class=\"nounderline abstract_t\">Miller S, Lagrata S, Watkins L, Matharu M. Occipital Nerve Stimulation for Medically Refractory Chronic Paroxysmal Hemicrania. Headache 2017; 57:1610.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/38\" class=\"nounderline abstract_t\">Tso AR, Marin J, Goadsby PJ. Noninvasive Vagus Nerve Stimulation for Treatment of Indomethacin-Sensitive Headaches. JAMA Neurol 2017; 74:1266.</a></li><li><a href=\"https://www.uptodate.com/contents/paroxysmal-hemicrania-treatment-and-prognosis/abstract/39\" class=\"nounderline abstract_t\">Walcott BP, Bamber NI, Anderson DE. Successful treatment of chronic paroxysmal hemicrania with posterior hypothalamic stimulation: technical case report. Neurosurgery 2009; 65:E997; discussion E997.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3335 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H15\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PHARMACOLOGIC TREATMENTS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Indomethacin</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">- Dosage and side effects</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">- Indomethacin discontinuation</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">Alternative drug therapies</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">- Other nonsteroidal antiinflammatory drugs</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">- Calcium channel antagonists</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">- Miscellaneous drugs</a></li></ul></li><li><a href=\"#H11812155\" id=\"outline-link-H11812155\">Children</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">ALTERNATIVE THERAPIES</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Local blockades</a></li><li><a href=\"#H1058603974\" id=\"outline-link-H1058603974\">Neurostimulation</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Invasive surgery</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">NATURAL HISTORY AND PROGNOSIS</a></li><li><a href=\"#H678085210\" id=\"outline-link-H678085210\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEURO/3335|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/65541\" class=\"graphic graphic_table\">- Clinical features of TACs</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=cox-2-selective-inhibitors-adverse-cardiovascular-effects\" class=\"medical medical_review\">COX-2 selective inhibitors: Adverse cardiovascular effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cluster-headache-epidemiology-clinical-features-and-diagnosis\" class=\"medical medical_review\">Cluster headache: Epidemiology, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hemicrania-continua\" class=\"medical medical_review\">Hemicrania continua</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nsaids-including-aspirin-primary-prevention-of-gastroduodenal-toxicity\" class=\"medical medical_review\">NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nonselective-nsaids-overview-of-adverse-effects\" class=\"medical medical_review\">Nonselective NSAIDs: Overview of adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=paroxysmal-hemicrania-clinical-features-and-diagnosis\" class=\"medical medical_review\">Paroxysmal hemicrania: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-of-the-trigeminal-autonomic-cephalalgias\" class=\"medical medical_review\">Pathophysiology of the trigeminal autonomic cephalalgias</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=short-lasting-unilateral-neuralgiform-headache-attacks-clinical-features-and-diagnosis\" class=\"medical medical_review\">Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-migraine-and-other-primary-headache-disorders\" class=\"medical medical_society_guidelines\">Society guideline links: Migraine and other primary headache disorders</a></li></ul></div></div>","javascript":null}